KPV

KPV (Lys-Pro-Val) is a tripeptide derived from alpha-MSH with strong anti-inflammatory, antimicrobial, and antifungal properties. It is being explored for use in inflammatory bowel diseases, topical inflammatory skin conditions, and systemic inflammation. Multiple delivery routes have been studied, including oral, SubQ, and topical forms.

• Inhibition of NF-kB activation, blocking inflammatory cascade
• Reduction of pro-inflammatory cytokines such as IL-6 and TNF-α
• Supports mucosal immunity and barrier restoration

• unit: mcg

  low dose: 100

  frequency: Daily

  high dose: 500

  standard dose: 250

  administration route: Oral

• unit: mcg

  low dose: 100

  frequency: daily

  high dose: 500

  standard dose: 250

  administration route: Subcutaneous (SQ)

• Typical dose: 250–500 mcg/day in capsule form. Can be taken long-term under supervision for chronic gut inflammation.
• 200–400 mcg daily SubQ recommended for systemic anti-inflammatory effects. Use in 4–8 week cycles with evaluation.

common: ["Mild flu-like symptoms (user-reported)","Temporary orange skin stain from topical application (user-reported)"]

long term: ["No dedicated human safety studies exist"]

sequence: Lys-Pro-Val

half life: Approximately 2 hours

degradation: Broken down by peptidases; stable in topicals and encapsulated delivery systems

molecular weight: 282.38

molecular formula: C15H26N2O3

tissue specificity: Targets gut epithelium, skin layers, and mucosal immune sites

• Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-MSH peptides.mechanismPMID 12750433 ↗
• Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine IBD models.preclinicalPMID 18092346 ↗
• Anti-inflammatory effects of alpha-MSH related peptides beyond the pharmacophore.reviewPMID 21222263 ↗